SG10201707518YA - Human antibodies to grem 1 - Google Patents
Human antibodies to grem 1Info
- Publication number
- SG10201707518YA SG10201707518YA SG10201707518YA SG10201707518YA SG10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA SG 10201707518Y A SG10201707518Y A SG 10201707518YA
- Authority
- SG
- Singapore
- Prior art keywords
- grem
- human antibodies
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782874P | 2013-03-14 | 2013-03-14 | |
| US201361883218P | 2013-09-27 | 2013-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201707518YA true SG10201707518YA (en) | 2017-10-30 |
Family
ID=50390267
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506459PA SG11201506459PA (en) | 2013-03-14 | 2014-03-07 | Human antibodies to grem 1 |
| SG10201707518YA SG10201707518YA (en) | 2013-03-14 | 2014-03-07 | Human antibodies to grem 1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201506459PA SG11201506459PA (en) | 2013-03-14 | 2014-03-07 | Human antibodies to grem 1 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10377817B2 (en) |
| EP (1) | EP2970448B1 (en) |
| JP (2) | JP6581075B2 (en) |
| KR (1) | KR20150129718A (en) |
| CN (1) | CN105189548A (en) |
| AU (1) | AU2014241442B2 (en) |
| BR (1) | BR112015021979A2 (en) |
| CA (1) | CA2904644C (en) |
| CL (1) | CL2015002603A1 (en) |
| EA (1) | EA201591762A1 (en) |
| ES (1) | ES2898620T3 (en) |
| HK (1) | HK1220469A1 (en) |
| IL (1) | IL240769A0 (en) |
| MX (1) | MX369574B (en) |
| PH (1) | PH12015501865A1 (en) |
| SG (2) | SG11201506459PA (en) |
| WO (1) | WO2014159010A1 (en) |
| ZA (1) | ZA201506113B (en) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013137686A1 (en) * | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | Gremlin-1 antibody |
| ES2898620T3 (en) | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Human antibodies against GREM 1 |
| BR112018071307A2 (en) | 2016-04-18 | 2019-02-26 | Celldex Therapeutics, Inc. | human cd40 binding agonist antibodies and uses thereof |
| CN106399316B (en) * | 2016-08-26 | 2019-03-01 | 西安交通大学第一附属医院 | The nucleic acid aptamer of Gremlin-1 and its application for identification |
| WO2018044640A1 (en) | 2016-08-29 | 2018-03-08 | Regeneron Pharmaceuticals, Inc. | Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension |
| CN110234348A (en) | 2016-12-16 | 2019-09-13 | 蓝鳍生物医药公司 | Anti- domain protein containing CUB 1 (CDCP1) antibody, antibody drug conjugate and its application method |
| GB201621635D0 (en) * | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| US11312769B2 (en) | 2017-03-22 | 2022-04-26 | Bluefin Biomedicine, Inc. | Anti-TMEFF1 antibodies and antibody drug conjugates |
| GB201802486D0 (en) * | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| MX2020013808A (en) * | 2018-06-18 | 2021-05-27 | UCB Biopharma SRL | Gremlin-1 antagonist for the prevention and treatment of cancer. |
| WO2020106461A2 (en) * | 2018-11-08 | 2020-05-28 | Celldex Therapeutics, Inc. | Anti-mertk antibodies and methods of use thereof |
| KR20220131894A (en) * | 2019-11-21 | 2022-09-29 | 유니티 바이오테크놀로지, 인크. | Antibodies directed to TIE-2 and methods of use |
| AU2021366287A1 (en) | 2020-10-20 | 2023-04-13 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof |
| WO2022150654A2 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| KR20230132544A (en) * | 2021-01-18 | 2023-09-15 | 쑤저우 트랜스센타 테라퓨틱스 컴퍼니 리미티드 | Novel anti-gremlin 1 antibody |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| WO2023203177A1 (en) * | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
| WO2024017241A1 (en) * | 2022-07-18 | 2024-01-25 | Suzhou Transcenta Therapeutics Co., Ltd. | Stable pharmaceutical formulation comprising anti-gremlin1 antibody |
| CN117801109B (en) * | 2024-03-01 | 2024-05-03 | 再少年(北京)生物科技有限公司 | Method for inducing directional differentiation of iPS into endothelial progenitor cells and application |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2437213A1 (en) | 1978-09-28 | 1980-04-25 | Cm Ind | CYTOTOXIC PRODUCTS FORMED BY COVALENT BINDING OF THE CHAIN TO RICIN WITH AN ANTIBODY AND THEIR PREPARATION METHOD |
| WO1998033918A1 (en) | 1997-02-05 | 1998-08-06 | The Regents Of The University Of California | Morphogenic proteins |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6573096B1 (en) | 2000-04-01 | 2003-06-03 | The Research Foundation At State University Of New York | Compositions and methods for inhibition of cancer invasion and angiogenesis |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1738767A1 (en) | 2001-10-31 | 2007-01-03 | Alcon, Inc. | Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma |
| DE60217152T2 (en) | 2001-10-31 | 2007-10-31 | Alcon Inc. | BONE MORPHOGENIC PROTEINS (BMP), BMP RECEPTORS AND BMP BINDING PROTEINS AND THEIR USE IN DIAGNOSIS AND TREATMENT OF GLUCKOM |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| EP1740946B1 (en) | 2004-04-20 | 2013-11-06 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| EP1855722A2 (en) | 2005-02-24 | 2007-11-21 | Novo Nordisk Health Care AG | Compounds for stabilizing factor vii polypeptide formulations |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US7411046B2 (en) | 2005-08-02 | 2008-08-12 | Arius Research Inc | Cancerous disease modifying antibodies |
| WO2007081751A2 (en) | 2006-01-05 | 2007-07-19 | The Johns Hopkins University | Compositions and methods for the treatment of cancer |
| US7420040B2 (en) | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
| US20090203041A1 (en) | 2006-04-21 | 2009-08-13 | Wei Shi | Bmp4 inhibitors |
| ES2398076T3 (en) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies against the human IL-6 receptor |
| US8383349B2 (en) | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| EP2136788B1 (en) | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| MX2011014008A (en) | 2009-06-26 | 2012-06-01 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format. |
| WO2013137686A1 (en) | 2012-03-15 | 2013-09-19 | 서울대학교 산학협력단 | Gremlin-1 antibody |
| ES2898620T3 (en) | 2013-03-14 | 2022-03-08 | Regeneron Pharma | Human antibodies against GREM 1 |
-
2014
- 2014-03-07 ES ES14713709T patent/ES2898620T3/en active Active
- 2014-03-07 US US14/775,637 patent/US10377817B2/en active Active
- 2014-03-07 CN CN201480014151.0A patent/CN105189548A/en active Pending
- 2014-03-07 CA CA2904644A patent/CA2904644C/en active Active
- 2014-03-07 EA EA201591762A patent/EA201591762A1/en unknown
- 2014-03-07 BR BR112015021979A patent/BR112015021979A2/en not_active Application Discontinuation
- 2014-03-07 KR KR1020157024673A patent/KR20150129718A/en not_active Application Discontinuation
- 2014-03-07 SG SG11201506459PA patent/SG11201506459PA/en unknown
- 2014-03-07 JP JP2016500767A patent/JP6581075B2/en active Active
- 2014-03-07 EP EP14713709.5A patent/EP2970448B1/en active Active
- 2014-03-07 WO PCT/US2014/021471 patent/WO2014159010A1/en active Application Filing
- 2014-03-07 SG SG10201707518YA patent/SG10201707518YA/en unknown
- 2014-03-07 AU AU2014241442A patent/AU2014241442B2/en active Active
- 2014-03-07 MX MX2015011616A patent/MX369574B/en active IP Right Grant
-
2015
- 2015-08-21 ZA ZA2015/06113A patent/ZA201506113B/en unknown
- 2015-08-23 IL IL240769A patent/IL240769A0/en unknown
- 2015-08-25 PH PH12015501865A patent/PH12015501865A1/en unknown
- 2015-09-11 CL CL2015002603A patent/CL2015002603A1/en unknown
-
2016
- 2016-07-18 HK HK16108451.7A patent/HK1220469A1/en unknown
-
2019
- 2019-05-08 JP JP2019087970A patent/JP2019151654A/en active Pending
- 2019-06-27 US US16/454,663 patent/US11634480B2/en active Active
-
2023
- 2023-03-06 US US18/117,883 patent/US20230192831A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2898620T3 (en) | 2022-03-08 |
| EA201591762A1 (en) | 2015-12-30 |
| CL2015002603A1 (en) | 2016-03-04 |
| US20160024195A1 (en) | 2016-01-28 |
| SG11201506459PA (en) | 2015-09-29 |
| CA2904644A1 (en) | 2014-10-02 |
| JP6581075B2 (en) | 2019-09-25 |
| AU2014241442B2 (en) | 2018-11-15 |
| AU2014241442A1 (en) | 2015-10-15 |
| IL240769A0 (en) | 2015-10-29 |
| US10377817B2 (en) | 2019-08-13 |
| JP2019151654A (en) | 2019-09-12 |
| WO2014159010A1 (en) | 2014-10-02 |
| EP2970448A1 (en) | 2016-01-20 |
| BR112015021979A2 (en) | 2017-08-29 |
| PH12015501865A1 (en) | 2015-12-07 |
| JP2016519650A (en) | 2016-07-07 |
| EP2970448B1 (en) | 2021-11-03 |
| MX369574B (en) | 2019-11-13 |
| US20230192831A1 (en) | 2023-06-22 |
| CA2904644C (en) | 2022-09-20 |
| KR20150129718A (en) | 2015-11-20 |
| CN105189548A (en) | 2015-12-23 |
| ZA201506113B (en) | 2016-07-27 |
| MX2015011616A (en) | 2015-12-17 |
| HK1220469A1 (en) | 2017-05-05 |
| US20200157194A1 (en) | 2020-05-21 |
| US11634480B2 (en) | 2023-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL240769A0 (en) | Human antibodies to grem 1 | |
| HK1220468A1 (en) | Human antibodies to nav1.7 nav17 | |
| IL262804A (en) | Human pac1 antibodies | |
| GB2510579B (en) | Zipper | |
| HK1219961A1 (en) | Human anti-ifn-alpha antibodies | |
| HK1219962A1 (en) | Human anti-il-32 antibodies -32 | |
| GB201312513D0 (en) | 2 4 1 Technology | |
| EP2955226A4 (en) | Antibodies to human nrg1 protein | |
| GB201322203D0 (en) | Deens' merger | |
| GB201322250D0 (en) | Human targets l | |
| GB201322568D0 (en) | Taggstar 1 | |
| GB201310748D0 (en) | Student's clinic | |
| GB201313605D0 (en) | Novel compounds and their use | |
| GB201310407D0 (en) | Plantladders 3 | |
| GB201310285D0 (en) | Twist-Away 270 | |
| GB201311486D0 (en) | Concept 50 | |
| GB201311488D0 (en) | Concept 51 | |
| GB201311483D0 (en) | Concept 48 | |
| GB201311469D0 (en) | Concept 12 12 | |
| GB201311489D0 (en) | Concept 52 | |
| GB201311501D0 (en) | Concept 37 | |
| GB201311490D0 (en) | Concept 53 | |
| GB201311528D0 (en) | Concept 44 | |
| GB201311529D0 (en) | Concept 3 | |
| GB201311491D0 (en) | Concept 54 |